> Sequence data has more potential than GWAS ever had, e.g. finding rare mutations. Sequencing studies really don't show this. Sequencing finds rare variants.

> Sequence data has more potential than GWAS ever had, e.g. finding rare mutations. Sequencing studies really don't show this. Sequencing finds rare variants. GWAS finds loci with common variants. We know that for many common diseases, the population-level variability due to rare variants is small. If you want to find drug targets, there is plenty of reason to use both approaches.